In light of these comparisons and the complexity of the findings, it is important to emphasize that our systematic review and meta-analyses are the first to comprehensively evaluate the efficacy and safety of both VMAT-2 inhibitors (tetrabenazine, deutetrabenazine, and valbenazine) and dopamine stabilizers (pridopidine and ordopidine) specifically in Huntington’s chorea. This evidence concerns the gene SLC18A2 and Huntington disease.